Goldman Sachs Maintains Krystal Biotech (KRYS) Buy Recommendation

Fintel reports that on May 22, 2023, Goldman Sachs maintained coverage of Krystal Biotech (NASDAQ:KRYS) with a Buy recommendation.

admin